Navigation Links
Misonix, Inc. To Report Financial Results For The First Quarter Of Fiscal Year 2014 On Thursday, November 7, 2013
Date:11/4/2013

FARMINGDALE, N.Y., Nov. 4, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that it will report financial results for the first quarter of fiscal year 2014 ended September 30, 2013 on Thursday, November 7, 2013. The Company has scheduled a conference call that same day, Thursday, November 7, 2013, at 4:30 pm ET to review the results.

Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10036674. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.

About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Misonix Contact:

Investor Contact: Richard Zaremba

Joe Diaz 631-694-9555 Lytham Partners invest@misonix.com 602-889-9700info@misonix.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix, Inc. Announces Fourth Quarter and Fiscal Year 2013 Financial Results
2. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
3. InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
4. Mast Therapeutics Reports Third Quarter 2013 Financial Results
5. Sinovac to Host Conference Call to Report Third Quarter 2013 Unaudited Financial Results
6. Sellers of Unapproved Drugs Proliferate Online, Posing a Serious Threat to Global Public Health, Reports NABP
7. Four-Star Gen. Barry McCaffrey, Former US Drug Czar, To Report "Drugs In The Workplace -- Understated National Crisis" At Teamsters Health & Benefits Forum Fri., Nov. 8, 10:30 AM At NYC Grand Hyatt
8. Cambrex Reports Third Quarter 2013 Financial Results
9. IRIDEX Reports 2013 Third Quarter Results
10. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
11. Concord Medical to Report Third Quarter 2013 Financial Results on November 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... is offering holistic pediatric dentistry options for its patients on Long Island, New ... patient’s entire physical well being, and is one of the biggest trends in ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... ... ... Technique, technique, technique – with a dash of common sense. Those are ... exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain management specialist ... “Improper technique in lifting anything heavy or an attempt to lift too much can ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a leading ... that its iClinic V12.2 solution has achieved approval from National Center for Quality ... 2017 standards which emphasize team-based care with a significant focus on the care ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... Health at West Penn Hospital , a unique facility that will offer the ... Construction of the Center is underway with a scheduled opening in the fall ...
Breaking Medicine News(10 mins):